These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11852993)

  • 1. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.
    Pieretti M; Hopenhayn-Rich C; Khattar NH; Cao Y; Huang B; Tucker TC
    Cancer Invest; 2002; 20(1):11-23. PubMed ID: 11852993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
    Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
    Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
    Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
    Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
    Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
    Skírnisdóttir I; Seidal T; Sorbe B
    Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.
    Nadkarni NJ; Geest KD; Neff T; Young BD; Bender DP; Ahmed A; Smith BJ; Button A; Goodheart MJ
    Cancer Lett; 2013 Apr; 331(1):99-104. PubMed ID: 23268330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
    Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
    Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
    Bar JK; Harłozińska A; Popiela A; Noga L
    Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 14. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation.
    Garcia A; Bussaglia E; Machin P; Matias-Guiu X; Prat J
    Int J Gynecol Pathol; 2000 Apr; 19(2):152-7. PubMed ID: 10782412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity at 7q22 and mutation analysis of the CDP gene in human epithelial ovarian tumors.
    Neville PJ; Thomas N; Campbell IG
    Int J Cancer; 2001 Feb; 91(3):345-9. PubMed ID: 11169958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
    Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
    Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
    Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
    Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
    Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations distinguish different types of ovarian tumors.
    Pieretti M; Cavalieri C; Conway PS; Gallion HH; Powell DE; Turker MS
    Int J Cancer; 1995 Dec; 64(6):434-40. PubMed ID: 8550247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.